jaymiehemonc

Cancer cells produce substances that “thicken” the blood, so men and women with cancer have a significantly higher risk of developing blood clots. A manifestation of blood clots can be cardiovascular events such as heart attack and stroke. The latest research found that six months after diagnosis, people with cancer had a higher rate of heart attack or stroke.

New research from Weill Cornell Medicine (WCM), published in the Journal of the American College of Cardiology, found that patients newly diagnosed with cancer are more than twice as likely to suffer from arterial thromboembolism – a sudden interruption of blood flow to an organ or body part due to a clot that has come from another part of the body – as cancer-free patients. The types of cancers studied include breast, lung, prostate, colorectal, bladder, pancreatic and gastric cancer.

Dr. Babak B. Navi, neurologist at Weill Cornell Medicine, and his team evaluated the risk of heart attack and stroke in patients age 66 or older with new cancer diagnoses compared with people who did not have cancer. Results showed that six months after diagnosis, people with cancer had a higher rate of heart attack or stroke (4.7%) due to blood clots than people without cancer (2.2%). After the first six months, the differences in risk got smaller. One year after diagnosis, the risks were about the same in people with and without cancer. Dr. Babak Navi and his team also discovered that more advanced stages of cancer were associated with higher risk.

This research is an outgrowth of the data that Dr. Babak Navi presented at last year’s International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) about the risk of heart attacks and stroke in women with breast cancer. Results showed that women diagnosed with breast cancer have a higher risk of a heart attack or stroke in the first year after diagnosis compared to similar women without breast cancer.

Through the latest research, we now know the risk of clotting goes beyond breast cancer and is a risk factor for many different forms of cancer. Further research is needed in order to develop optimal strategies to prevent arterial thromboembolism in patients with cancer.

Weill Cornell Medicine

“People with cancer are known to be at increased risk of blood clots and this risk is believed to vary according to cancer type, stage of disease, and treatment modality. We also know that patients with cancer are more likely to have cardiovascular events which may be induced by tumor or its treatment,” says Dr. Scott Tagawa, medical oncologist and Director of the Weill Cornell Medicine Genitourinary (GU) Oncology Program. “This research further underscores the need to conduct clinical trials to determine the best prevention methods and treatment of thrombosis in patients with cancer.”

Mark your calendars to learn more about the cancer clotting connection at this year’s World Thrombosis Day event.

061_WTD_2017_Invite_v2

The Weill Cornell Medicine and NewYork-Presbyterian Genitourinary Oncology Program is proud to announce that our physicians have been identified as Castle Connolly 2017 Top Doctors for cancer in the United States and in the New York Metro area. This further validates our long-standing commitment to patient care and the advancement of medicine.

Collage — *WCM/NYP Genitourinary (GU) Medical Oncologists*

Each year, Castle Connolly, an established healthcare research company located in New York, bases its selection through a peer-review process, extensive research and screening of nearly 100,000 nominations. This nomination shows that not only do our physicians have a great reputation, but they are also recognized by other doctors who can attest to their commitment to the field of genitourinary oncology.

“Within the Genitourinary Oncology Program, we are dedicated to providing cutting-edge care and access to clinical trials for people with all stages and types of prostate, kidney, bladder and testicular cancer,” said Scott Tagawa, MD, Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine.

Diagnosing and using the latest technologies to molecularly characterize and find the right treatment for each patient is an individualized process. Physicians in the Genitourinary Oncology Program, as well as other cancer experts throughout Weill Cornell Medicine and NewYork-Presbyterian, utilize an approach to treatment known as precision medicine that assesses individual variability in the tumor’s genes and microenvironment. This allows our physicians and researchers to better understand and predict which treatment approach will work best for each patient, without using a “one-size-fits-all” approach.

According to Dr. Tagawa, “Patient care is our utmost priority and winning this prestigious Castle Connolly Top Doctors award is a testament to our dedication to improving the lives of our patients. I’m honored to be part of such a comprehensive and multidisciplinary team.”

Congratulations to the GU physicians on this outstanding achievement!

About Castle Connolly and America’s Top Doctors

The mission of Castle Connolly Medical Ltd. is to help consumers find the best healthcare. They publish a variety of books including the “Top Doctors” series, the most popular of which is America’s Top Doctors®. Doctors who are among the very best in their specialties and in their communities are selected for inclusion.